Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Indirect Comparison Study Shows PFS Superiority for Zanubrutinib vs Acalabrutinib in CLL

March 1st 2024

An indirect comparison study in relapsed/refractory chronic lymphocytic leukemia demonstrated survival benefits with zanubrutinib vs acalabrutinib.

FDA Approves Label Expansion for Oral Ibrutinib Suspension in All Current Indications

February 28th 2024

The FDA has approved a label expansion for ibrutinib with an oral suspension formulation in all current indications.

Revisit Every OncLive On Air Episode From January 2024

February 26th 2024

In case you missed it, read a recap of every episode of OncLive On Air recorded in January 2024.

Liso-Cel Demonstrates Durable Efficacy in Relapsed/Refractory CLL/SLL

February 23rd 2024

Lisocabtagene maraleucel elicited durable responses in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Increased Understanding of CLL Tumor Biology Unlocks Targeted CAR T-Cell Approaches

February 22nd 2024

Jan Joseph Melenhorst, PhD, emphasizes how research investigating chronic lymphocytic leukemia biology may result in more targeted CAR T-cell products.

Liso-Cel Maintains Longer-Term Responses in Pretreated Relapsed/Refractory CLL/SLL

February 21st 2024

Tatyana Feldman, MD, highlights updated data for liso-cel in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Unlocking Long-Term Success: Insights From 5-Year Follow-Up of the CAPTIVATE Trial in CLL/SLL

February 20th 2024

Paolo Ghia, MD, PhD, discusses long-term efficacy data for fixed-duration ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia.

Future Perspectives on the Treatment Landscape for CLL

February 16th 2024

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in CLL.

Expert Insights into Investigation Therapies for CLL

February 16th 2024

Expert oncologists explore emerging therapies being investigated in CLL, including BTKi degraders, CAR-T therapy, and bispecific antibodies, and discussed their potential impact in shaping the future of CLL treatment.

Dr Choi on the Implications of Approving Liso-Cel in Patients With CLL

February 15th 2024

Michael Choi, MD, discusses the potential FDA approval of lisocabtagene maraleucel in patients with relapsed/refractory chronic lymphocytic leukemia.

Dr Feldman on the Background of the TRANSCEND CLL 004 Trial in CLL/SLL

February 13th 2024

Tatyana Feldman, MD, discusses the launch of the TRANSCEND CLL 004 trial in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Emerging Data Surrounding Mechanisms of Resistance to Non-Covalent BTKis

February 9th 2024

The expert panel discusses recent data regarding the mechanisms of resistance to non-covalent BTK inhibitors in CLL.

Role of Non-Covalent BTKis in R/R CLL: Updates from Ongoing BRUIN and Bellwave Trials

February 9th 2024

Jacqueline Barrientos, MD, MS, discusses the role of non-covalent BTK inhibitors in R/R CLL and provided concise comments on the latest data, including insights from the ongoing BRUIN and Bellwave trials.

Dr Coombs on Notable BTK Inhibitor Combination Studies in CLL

February 8th 2024

Callie Coombs, MD, discusses the investigation of notable BTK inhibitor combination trials in patients with chronic lymphocytic leukemia.

Treatment Resistance with Covalent BTKis: Translating Data into Clinical Practice

February 2nd 2024

Javier Pinilla, MD, PhD explores evidence on molecular mechanisms leading to resistance in second-generation BTK inhibitors for CLL, providing insights from recently presented data at ASH 2023.

Expert Insights into Navigating Cardiovascular Risks with BTKi Therapy

February 2nd 2024

A panel of expert oncologists explore the influence of hypertension risk and other cardiovascular AEs in guiding treatment selection with BTKis, sharing insights from ASH 2023.

Expert Perspectives on Navigating Treatment Selection with BTKis in CLL

January 26th 2024

Faculty provide insights into the selection of BTK inhibitors, emphasizing the role of efficacy, toxicity, and quality of life data in treatment decisions, and exploring the impact of MAIC data.

Navigating BTKi Therapy in R/R CLL: Updates from ELEVATE-RR and ALPINE

January 26th 2024

Panel experts examine considerations for BTKi-based strategies in R/R CLL, highlighting pivotal findings from head-to-head trials, including acalabrutinib vs ibrutinib in ELEVATE-RR and zanubrutinib vs ibrutinib in ALPINE, covering safety, quality of life, and extended follow-up data.

Dr Dholaria on the Investigation of Noncovalent BTK Inhibitors in CLL

January 25th 2024

Bhagirathbhai Dholaria, MBBS, discusses the ongoing evaluation of noncovalent BTK inhibitors in patients with chronic lymphocytic leukemia.

Dr Davids on Treatment With Pirtobrutinib in CLL/SLL With/Without Prior BCL-2 Inhibitor Exposure

January 24th 2024

Matthew S. Davids, MD, MMSc, discusses key efficacy results from 2 follow-up analyses of the phase 1/2 BRUIN trial evaluating pirtobrutinib.